A talc lawsuit generally moves from individual filing through coordinated discovery, followed by settlement or trial. As of July 2026, a proposed $5.5 billion ovarian-cancer resolution remains incomplete, while some talc claims still face trial. Most federal cases proceed through multidistrict litigation, or MDL. An MDL places similar individual lawsuits before one judge for coordinated pretrial work; it does not turn them into a class action.
Official resources:
- Read the official notice from Uscourts — Use this primary source to verify the official announcement.
- Explore the official data from SEC — Use this primary source to review the underlying data.
Table of Contents
- Filing started with individual lawsuits
- What happens during coordinated discovery?
- Why earlier settlement efforts did not end the litigation
- Where the proposed $5.5 billion resolution stands
- Trial remains possible for claims outside the proposal
Filing started with individual lawsuits
The federal talc docket began as separate personal-injury lawsuits. On October 4, 2016, the Judicial Panel on Multidistrict Litigation centralized 11 actions from 10 districts, along with 43 related actions, in new Jersey as MDL 2738. Plaintiffs alleged that Johnson & Johnson powders caused ovarian or uterine cancer.
The cases shared questions about cancer risk, the defendants' knowledge, and whether product warnings were adequate, according to the Judicial Panel's transfer order. This structure matters when evaluating settlement news. A proposal covering many MDL and state-court claims is not necessarily a nationwide class settlement that automatically binds every claimant.
What happens during coordinated discovery?
Discovery is the evidence-gathering stage. The MDL coordinates document production, testimony, expert evidence, and disputes that affect many lawsuits. Coordination reduces repeated discovery and inconsistent rulings on whether expert testimony is admissible. Expert evidence can determine whether an individual claim survives. Plaintiffs generally need evidence connecting the product to the particular person's cancer, known as specific causation.
That issue became critical in two bellwether cases, which are selected to test recurring evidence and arguments. Johnson & Johnson reported that the plaintiffs withdrew their specific-causation experts after a hearing. On July 22, 2026, the MDL court ordered plaintiffs to explain why remaining claims should not be dismissed for inability to prove specific causation, according to the company's July 2026 litigation announcement. The order does not itself establish that every remaining claim has been dismissed. It does show why expert proof can influence settlement leverage, case value, and whether a lawsuit reaches trial.
Why earlier settlement efforts did not end the litigation
A proposed settlement is not final merely because the parties announce a dollar amount. It may depend on court approval, claimant participation, releases, or another legal process. One earlier attempt relied on bankruptcy.
📨 Get Free Mass Tort Guides Alerts
Free · No spam · Unsubscribe anytime
On March 31, 2025, a Texas bankruptcy judge rejected Johnson & Johnson's proposed $10 billion plan, citing insufficient support and problems with releases for parties that were not debtors, as reported by Reuters. Because that plan did not take effect, it did not produce the proposed global resolution. Claimants should distinguish a rejected plan from an active offer and an active offer from a completed payment program.
Where the proposed $5.5 billion resolution stands
On July 27, 2026, Johnson & Johnson announced a proposed $5.5 billion resolution covering remaining ovarian-talc litigation in the federal MDL and related state cases. The proposal uses per-claim payments, with no more than $3 billion due in 2027, according to the company's SEC filing. The proposal requires express participation by plaintiff firms representing at least 95% of the remaining claims.
Johnson & Johnson estimated that approximately 76,000 claims remained. Until that threshold and the proposal's other requirements are satisfied, the announcement should not be described as a completed universal settlement. The available figures also do not establish what any individual claimant would receive. "Per-claim payments" does not mean equal payments, and the supplied evidence does not provide an allocation formula, payment schedule for each claimant, or individual eligibility rules.
Trial remains possible for claims outside the proposal
The proposed resolution concerns ovarian-talc litigation. Trial risk remains relevant for other alleged injuries, including mesothelioma claims.
In October 2025, a Los Angeles jury awarded $966 million to a mesothelioma claimant's family. Johnson & Johnson said it would appeal and reported that it had already settled about 95% of filed mesothelioma lawsuits, according to Reuters. A claimant assessing the timeline should ask counsel for case-specific answers: Before relying on a settlement announcement, request written confirmation that identifies the covered claim, required release, expected deductions, and any decision deadline.
- Is the claim in the federal MDL, a state court, or another proceeding?
- Does the proposed ovarian resolution cover the diagnosed cancer?
- Has the claimant's law firm expressly agreed to participate?
- What expert evidence supports specific causation?
- What releases, deductions, deadlines, or appeal risks affect payment?
You Might Also Like
- Toxic Exposure Lawsuit FAQ: Rights, Deadlines, and Legal Process
- Class Action Settlement Guide: Terms, Payments, and Release Language
- Class Action Settlement Filing Evidence Guide: Documents, Experts, and Causation